These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
607 related articles for article (PubMed ID: 26103617)
1. Therapeutic approaches of magnetic nanoparticles for the central nervous system. Dilnawaz F; Sahoo SK Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617 [TBL] [Abstract][Full Text] [Related]
2. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Begley DJ Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907 [TBL] [Abstract][Full Text] [Related]
3. Magnetic hybrid nanovesicles for the precise diagnosis and treatment of central nervous system disorders. Salatin S; Farhoudi M; Sadigh-Eteghad S; Mahmoudi J Expert Opin Drug Deliv; 2024 Apr; 21(4):521-535. PubMed ID: 38555483 [TBL] [Abstract][Full Text] [Related]
4. Nanotechnology-based drug delivery for central nervous system disorders. Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020 [TBL] [Abstract][Full Text] [Related]
5. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Vlieghe P; Khrestchatisky M Med Res Rev; 2013 May; 33(3):457-516. PubMed ID: 22434495 [TBL] [Abstract][Full Text] [Related]
6. Nanotechnological advances for the delivery of CNS therapeutics. Wong HL; Wu XY; Bendayan R Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125 [TBL] [Abstract][Full Text] [Related]
7. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery. Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455 [TBL] [Abstract][Full Text] [Related]
8. Differential receptor-mediated drug targeting to the diseased brain. Rip J; Schenk GJ; de Boer AG Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042 [TBL] [Abstract][Full Text] [Related]
9. [Research advances in brain-targeted nanoscale drug delivery system]. Liu Y; Jiang C Yao Xue Xue Bao; 2013 Oct; 48(10):1532-43. PubMed ID: 24417079 [TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Gao H; Pang Z; Jiang X Pharm Res; 2013 Oct; 30(10):2485-98. PubMed ID: 23797465 [TBL] [Abstract][Full Text] [Related]
11. Applications of nanotechnology in drug delivery to the central nervous system. Saeedi M; Eslamifar M; Khezri K; Dizaj SM Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991 [TBL] [Abstract][Full Text] [Related]
12. Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides. Qian S; Wang Q; Zuo Z Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1491-508. PubMed ID: 25196358 [TBL] [Abstract][Full Text] [Related]
13. Application of modelling and nanotechnology-based approaches: The emergence of breakthroughs in theranostics of central nervous system disorders. Hassanzadeh P; Atyabi F; Dinarvand R Life Sci; 2017 Aug; 182():93-103. PubMed ID: 28583367 [TBL] [Abstract][Full Text] [Related]
14. Polymeric nanoparticles for the drug delivery to the central nervous system. Tosi G; Costantino L; Ruozi B; Forni F; Vandelli MA Expert Opin Drug Deliv; 2008 Feb; 5(2):155-74. PubMed ID: 18248316 [TBL] [Abstract][Full Text] [Related]
15. Nanobiotechnology-based drug delivery to the central nervous system. Jain KK Neurodegener Dis; 2007; 4(4):287-91. PubMed ID: 17627131 [TBL] [Abstract][Full Text] [Related]
16. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders. Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087 [TBL] [Abstract][Full Text] [Related]
17. Nano-enabled delivery systems across the blood-brain barrier. Hwang SR; Kim K Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511 [TBL] [Abstract][Full Text] [Related]
18. Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders. Sharma A; Manchanda R; Pottoo FH; Ashraf GM Curr Drug Metab; 2021; 22(4):251-262. PubMed ID: 33234099 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications. Mosayebi J; Kiyasatfar M; Laurent S Adv Healthc Mater; 2017 Dec; 6(23):. PubMed ID: 28990364 [TBL] [Abstract][Full Text] [Related]
20. Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance. Mc Carthy DJ; Malhotra M; O'Mahony AM; Cryan JF; O'Driscoll CM Pharm Res; 2015 Apr; 32(4):1161-85. PubMed ID: 25446769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]